Ximelagatran: Oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation

Journal of the American College of Cardiology

Volumn 45, Issue 1, 2005, Pages 1-9

  Halperin, Jonathan L ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ATORVASTATIN; DALTEPARIN; DIAZEPAM; DICLOFENAC; DIGOXIN; ENOXAPARIN; ERYTHROMYCIN; MELAGATRAN; NIFEDIPINE; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPETITIVE INHIBITION; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; META ANALYSIS; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; STROKE; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 11144240085     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.09.049     Document Type: Review

References (56)

1. G.W. Albers, J.E. Dalen, A. Laupacis, W.J. Manning, P. Petersen, D.E. Singer Antithrombotic therapy in atrial fibrillation Chest 119 2001 194S 206S
2. R.G. Hart Atrial fibrillation and stroke prevention N Engl J Med 349 2003 1015 1016
3. M. Karatas, A. Dilek, H. Erkan, N. Yavuz, S. Sozay, N. Akman Functional outcome in stroke patients with atrial fibrillation Arch Phys Med Rehabil 81 2000 1025 1029
4. D.A. Dulli, H. Stanko, R.L. Levine Atrial fibrillation is associated with severe acute ischemic stroke Neuroepidemiology 22 2003 118 123
5. R.G. Hart, S. Palacio, L.A. Pearce Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials Stroke 33 2002 2722 2727
6. D.M. Lloyd-Jones, T.J. Wang, E.P. Leip Lifetime risk for development of atrial fibrillation: the Framingham Heart study Circulation 110 2004 1042 1046
7. A.S. Go, E.M. Hylek, K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults--national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study JAMA 285 2001 2370 2375
8. J.S. Steinberg Atrial fibrillation: an emerging epidemic? Heart 90 2004 239 240
9. S. Stewart, N. Murphy, A. Walker, A. McGuire, J.J.V. McMurray Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK Heart 90 2004 286 292
10. V. Fuster, L.E. Rydén, R.W. Asinger ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology J Am Coll Cardiol 38 2001 1231 1265
11. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
12. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
13. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688-95.
14. M.C. Fang, R.S. Stafford, J.N. Ruskin, D.E. Singer National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation Arch Intern Med 164 2004 55 60
15. L.Z. Benet, J.E. Goyan Bioequivalence and narrow therapeutic index drugs Pharmacotherapy 15 1995 433 440
16. M. Elg, D. Gustafsson, S. Carlsson Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat Thromb Res 94 1999 187 197
17. D. Gustafsson, J.-E. Nyström, S. Carlsson The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects Thromb Res 101 2001 171 181
18. D. Gustafsson, R. Bylund, T. Antonsson A new oral anticoagulant: the 50-year challenge Nat Rev Drug Discov 3 2004 649 659
19. U.G. Eriksson, U. Bredberg, K.-J. Hoffmann Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans Drug Metab Dispos 31 2003 294 305
20. Cohen AT, Agnelli G, Dahl OE, et al. Efficacy and safety of the treatment regimen of melagatran and ximelagatran for prevention of thromboembolic events after total hip or knee replacement: a meta-analysis of 3 randomized, double-blind studies, to evaluate the influence of time and dose (abstr CD-ROM). J Thromb Haemost 2003;1 Suppl 1.
21. J.A. Heit, C.W. Colwell, C.W. Francis Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study Arch Intern Med 161 2001 2215 2221
22. C.W. Francis, B.L. Davidson, S.D. Berkowitz Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial Ann Intern Med 137 2002 648 655
23. C.W.J. Colwell, S.D. Berkowitz, B.L. Davidson Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study J Thromb Haemost 1 2003 2119 2130
24. C.W. Francis, S.D. Berkowitz, P.C. Comp Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement N Engl J Med 349 2003 1703 1712
25. Colwell CW, Berkowitz SD, Comp PC, et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B (abstr). Blood 2003;102. Online only. Available at: http://www.abstracts2view. com/hem/.
26. H. Eriksson, K. Wåhlander, D. Gustafsson, L. Welin, L. Frison, S. Schulman A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I J Thromb Haemost 1 2003 41 47
27. C.W. Francis, J.S. Ginsberg, S.D. Berkowitz Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study (abstr 7) Blood 102 2003 6a
28. L. Wallentin, R.G. Wilcox, W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
29. M. Wolzt, S.L. Boström, M. Svensson, K. Wa·hlander, M. Grind, T.C. Sarich Effects of the oral direct thrombin inhibitor ximelagatran on P-selectin expression and thrombin generation in atrial fibrillation Pathophysiol Haemost Thromb 33 2003 68 74
30. M. Wolzt, M. Wollbratt, M. Svensson, K. Wåhlander, M. Grind, U.G. Eriksson Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and healthy subjects Eur J Clin Pharmacol 59 2003 537 543
31. U.G. Eriksson, S. Bååthe, B. Hamrén, M. Wollbratt, M. Wolzt, M. Grind Predictable pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in nonvalvular atrial fibrillation patients receiving long-term treatment (abstr) Pathophysiol Haemost Thromb 32 Suppl 2 2002 56
32. M. Grind, U.G. Eriksson, B. Hamrén, S. Bååthe, M. Wollbratt Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation receiving long-term treatment: a population analysis by nonlinear mixed effect modeling (abstr) Clin Pharmacol Ther 71 2002 31
33. D. Gustafsson, M. Elg The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review Thromb Res 109 2003 S9 15
34. E. Bredberg, T.B. Andersson, L. Frison Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions Clin Pharmacokinet 42 2003 765 777
35. G. Fager, M. Cullberg, M. Eriksson-Lepkowska, L. Frison, U.G. Eriksson Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid Eur J Clin Pharmacol 59 2003 283 289
36. T.C. Sarich, K.M. Schutzer, M. Wollbratt, U. Wall, E. Kessler, U.G. Eriksson No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers J Clin Pharmacol 44 2004 935 941
37. T.C. Sarich, K.M. Schutzer, H. Dorani No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran J Clin Pharmacol 44 2004 928 934
38. H. Dorani, K.-M. Schützer, T.C. Sarich, U. Wall, L. Ohlsson, U.G. Eriksson Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran (abstr) Clin Pharmacol Ther 75 2004 78
39. L.C. Johansson, L. Frison, U. Logren, G. Fager, D. Gustafsson, U.G. Eriksson Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor Clin Pharmacokinet 42 2003 381 392
40. L.C. Johansson, M. Andersson, G. Fager, D. Gustafsson, U.G. Eriksson No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers Clin Pharmacokinet 42 2003 475 484
41. T.C. Sarich, R. Teng, G.R. Peters No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran Clin Pharmacokinet 42 2003 485 492
42. U.G. Eriksson, U. Bredberg, K. Gislén Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects Eur J Clin Pharmacol 59 2003 35 43
43. T.C. Sarich, S. Johansson, K.-M. Schützer The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol J Clin Pharmacol 44 2004 388 393
44. P. Petersen, M. Grind, J. Adler SPORTIF II Investigators Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation SPORTIF II: A dose-guiding, tolerability, and safety study J Am Coll Cardiol 41 2003 1445 1451
45. Petersen P. A 2-year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (abstr). Neurology 2002;58 Suppl 3:A477.
46. J.L. Halperin Executive Steering Committee on behalf of the SPORTIF III and V Study Investigators Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) Am Heart J 146 2003 431 438
47. Executive Steering Committee on behalf of the SPORTIF III Investigators Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
48. S.B. Olsson Ximelagatran or warfarin in atrial fibrillation (reply)? Lancet 363 2004 736
49. M.K. Vadivelu Aspirin bias in SPORTIF III trial Lancet 363 2004 2091
50. S.B. Olsson Aspirin bias in SPORTIF III trial (reply) Lancet 363 2004 2091
51. Albers GW, for the Executive Steering Commitee on behalf of the SPORTIF Investigators. Pooled analysis of the SPORTIF III and V trials: secondary stroke prevention and stroke subtypes (abstr). Stroke 2004;35:242-3.
52. Executive Steering Committee on behalf of the SPORTIF V Investigators Efficacy and safety study of the oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V) (abstr) Circulation 108 2003 2723
53. G. Hankey, C.J. Klijn, J. Eikelboom Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation? Stroke 35 2004 389 391
54. G.A. Donnan, H.M. Dewey, B.R. Chambers Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 3 2004 305 308
55. F.W.A. Verheugt Can we pull the plug on warfarin in atrial fibrillation? Lancet 362 2003 1686 1687
56. S.G. Rockson, G.W. Albers Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation J Am Coll Cardiol 43 2004 929 935